Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis

Journal of Immunology

Volumn 174, Issue 11, 2005, Pages 7160-7171

  Basu, Rajatava ^a   Bhaumik, Suniti ^a   Basu, Jayati Mockerjee ^a   Naskar, Kshudiram ^a   De, Tripti ^a   Roy, Syamal ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; DNA VACCINE; GAMMA INTERFERON; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; KINETOPLASTID MEMBRANE PROTEIN 11; MEMBRANE PROTEIN; NITROGEN OXIDE; PENTAVALENT ANTIMONY; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DRUG MECHANISM; DRUG RESISTANCE; HAMSTER; IMMUNE RESPONSE; IMMUNOPATHOLOGY; KINETOPLAST; LEISHMANIA DONOVANI; MOUSE; NONHUMAN; PARASITE SURVIVAL; PARASITE VIRULENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; TH1 CELL; TH2 CELL; VACCINATION; VIRAL GENE THERAPY; VISCERAL LEISHMANIASIS;

EID: 18944378937     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.11.7160     Document Type: Article

References (80)

1. Carvalho, E. M., R. S. Teixeira, and W. D. Johnson, Jr. 1981. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect. Immun. 33: 498-502.
2. Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of γ interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76: 2066-2069.
3. Pintado, V., P. Martín-Rabadán, M. L. Rivera, S. Moreno, and E. Bouza. 2001. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: a comparative study. Medicine (Baltimore) 80: 54-73.
4. United Nations Development Program/World Bank/World Health Organization Special Programme for Research and Training in Tropical Diseases, 1989. In Tropical diseases: Progress in International Research, 1987-1988. Ninth Programme Report. UNDP/WB/WHO, Geneva, Switzerland, pp 128.
5. Melby, P. C., G. B. Ogden, H. A. Flores, W. Zhao, C. Geldmacher, N. M. Biediger, S. K. Ahuja, J. Uranga, and M. Melendez. 2000. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68: 5595-5602.
6. Kafetzis, D. A., and H. C. Maltezou. 2002. Visceral leishmaniasis in paediatrics. Curr. Opin. Infect. Dis. 15: 289-294.
7. Murray, H. W. 2001. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197.
8. Sundar, S., D. K. More, M. K. Singh, V. P. Singh, S. Sharma, A. Makharia, P. C. Kumar, and H. W. Murray. 2000. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin. Infect. Dis. 31: 1104-1107.
9. Perez-Victoria, J. M., F. J. Perez-Victoria, A. Parodi-Talice, I. A. Jimenez, A. G. Ravelo, S. Castanys, and F. Gamarro. 2001. Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator. Antimicrob. Agents Chemother. 45: 2468-2474.
10. Liew, F. Y., and C. A. O'Donnell. 1993. Immunology of leishmaniasis. Adv. Parasitol. 32: 161-259.
11. Bottrel, R. L., W. O. Dutra, F. A. Martins, B. Gontijo, E. Carvalho, M. Barral-Netto, A. Barral, R. P. Almeida, W. Mayrink, R. Locksley, and K. J. Gollob. 2001. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis. Infect. Immun. 69: 3232-3239.
12. Melby, P. C., V. V. Tryon, B. Chandrasekar, and G. L. Freeman. 1998. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun. 66: 2135-2142.
13. Jardim, A., S. Hanson, B. Ullman, W. D. McCubbin, C. M. Kay, and R. W. Olafson. 1995. Cloning and structure-function analysis of the Leishmania donovani kinetoplastid membrane protein-11. Biochem. J. 305: 315-320.
14. Jardim, A., V. Funk, R. M. Caprioli, and R. W. Olafson. 1995. Isolation and structural characterization of the Leishmania donovani kinetoplastid membrane protein-11, a major immunoreactive membrane glycoprotein. Biochem. J. 305: 307-313.
15. Berberich, C., G. Machado, G. Morales, G. Carrillo, A. Jimenez-Ruiz, and C. Alonso. 1998. The expression of the Leishmania infantum KMP-11 protein is developmentally regulated and stage specific. Biochim. Biophys. Acta 1442: 230-237.
16. Mukhopadhyay, S., P. Sen, S. Bhattacharyya, S. Majumdar, and S. Roy. 1999. Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. Vaccine 17: 291-300.
17. Kurtzhals, J. A., A. S. Hey, A. Jardim, M. Kemp, K. U. Schaefer, E. O. Odera, C. B. Christensen, J. I. Githure, R. W. Olafson, T. G. Theander, et al. 1994. Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan- associated protein in cells from cured visceral leishmaniasis patients. Clin. Exp. Immunol. 96: 416-421.
18. Requena, J. M., M. Soto, M. D. Doria, and C. Alonso. 2000. Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model. Vet. Immunol. Immunopathol 76: 269-281.
19. Kemp, M., A. S. Hey, J. A. Kurtzhals, C. B. Christensen, A. Gaafar, M. D. Mustafa, A. A. Kordofani, A. Ismail, A. Kharazmi, and T. G. Theander. 1994. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin. Exp. Immunol. 96: 410-415.
20. + cytotoxic T cell responses. Eur. J. Immunol. 24: 2813-2817.
21. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J. Immunol. 168: 3992-4000.
22. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186: 1137-1147.
23. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146: 2763-2770.
24. Kemp, K., M. Kemp, A. Kharazmi, A. Ismail, J. A. Kurtzhals, L. Hviid, and T. G. Theander. 1999. Leishmania-specific T cells expressing interferon-γ (IFN-γ) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin. Exp. Immunol. 116: 500-504.
25. Kemp, K. 2000. Cytokine-producing T cell subsets in human leishmaniasis. Arch. Immunol. Ther. Exp. 48: 173-177.
26. Kupper, T., P. Flood, D. Coleman, and M. Horowitz. 1987. Growth of an interleukin 2/interleukin 4-dependent T cell line induced by granulocyte-macrophage colony-stimulating factor (GM-CSF). J. Immunol. 138: 4288-4292.
27. Mukhopadhyay, R., and R. Madhubala. 1994. Antileishmanial activity and modification of hepatic xenobiotic metabolizing enzymes in golden hamster by 2(3)-tert-butyl-4-hydroxyanisole following infection with Leishmania donovani. Biochem. Pharmacol. 47: 253-256.
28. Bhattacharyya, A., M. Mukherjee, and S. Duttagupta. 2002. Studies on Stibanate unresponsive isolates of Leishmania donovani. J. Biosci. 27: 503-508.
29. McElrath, M. J., H. W. Murray, and Z. A. Cohn. 1988. The dynamics of granuloma formation in experimental visceral leishmaniasis. J. Exp. Med. 167: 1927-1937.
30. Melby, P. C., B. Chandrasekar, W. Zhao, and J. E. Coe. 2001. The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J. Immunol. 166: 1912-1920.
31. Rodrigues Junior, V., J. S. Da Silva, and A. Campos-Neto. 1992. Selective inability of spleen antigen presenting cells from Leishmania donovani infected hamsters to mediate specific T cell proliferation to parasite antigens. Parasite Immunol. 14: 49-58.
32. Roy, S., M. T. Scherer, T. J. Briner, J. A. Smith, and M. L. Gefter. 1989. Murine MHC polymorphism and T cell specificities. Science 244: 572-575.
33. 2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J. Biol Chem. 277: 24717-24127.
34. Berberich, C., J. M. Requena, and C. Alonso. 1997. Cloning of genes and expression and antigenicity analysis of the Leishmania infantum KMP-11 protein. Exp. Parasitol. 85: 105-108.
35. Murray, H. W., J. J. Stern, K. Welte, B. Y. Rubin, S. M. Carrier, and C. F. Nathan. 1987. Experimental visceral leishmaniasis: production of interleukin 2 and interferon-γ, tissue immune reaction, and response to treatment with interleukin 2 and interferon-γ. J. Immunol. 138: 2290-2297.
36. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185: 867-874.
37. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-γ: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-γ gene-disrupted mice. J. Exp. Med. 185: 1231-1239.
38. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68: 6289-6293.
39. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, and R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70: 6284-6293.
40. Haldar, J. P., S. Ghose, K. C. Sana, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42: 702-707.
41. Carvalho, E. M., O. Bacellar, C. Brownell, T. Regis, R. L. Coffman, and S. G. Reed. 1994. Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J. Immunol. 152: 5949-5956.
42. Gifawesen, C., and J. P. Farrell. 1989. Comparison of T-cell responses in self-limiting versus progressive visceral Leishmania donovani infections in golden hamsters. Infect. Immun. 57: 3091-3096.
43. Reiner, N. E., and J. H. Finke. 1983. Interleukin 2 deficiency in murine Leishmaniasis donovani and its relationship to depressed spleen cell responses to phytohemagglutinin. J. Immunol. 131: 1487-1491.
44. Cohen, A. D., J. D. Boyer, and D. B. Weiner. 1998. Modulating the immune response to genetic immunization. FASEB J. 12: 1611-1626.
45. Wang, R., D. L. Doolan, T. P. Le, R. C. Hedstrom, K. M. Coonan, Y. Charoenvit, T. R. Jones, P. Hobart, M. Margalith, J. Ng, et al. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480.
46. Kemp, M., J. A. Kurtzhals, K. Bendtzen, L. K. Poulsen, M. B. Hansen, D. K. Koech, A. Kharazmi, and T. G. Theander. 1993. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect. Immun. 61: 1069-1073.
47. Schneemann, M., G. Schoedon, S. Hofer, N. Blau, L. Guerrero, and A. Schaffner. 1993. Nitric oxide synthase is not a constituent of the antimicrobial armature of human mononuclear phagocytes. J. Infect. Dis. 167: 1358-1363.
48. Bhakuni, V., S. Kulkarni, V. Ali, U. K. Singh, H. B. Levy, and R. K. Maheshwari. 1999. Immunochemotherapy for Leishmania donovani infection in golden hamsters: combinatorial action of poly ICLC plus L-arginine and sodium stibogluconate (Stibanate). J. Interferon Cytokine Res. 19: 1103-1106.
49. Green, S. J., R. M. Crawford, J. T. Hockmeyer, M. S. Meltzer, and C. A. Nacy. 1990. Leishmania major amastigotes initiate the L-arginine-dependent killing mechanism in IFN-γ-stimulated macrophages by induction of tumor necrosis factor-α. J. Immunol. 145: 4290-4297.
50. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-α synergizes with IFN-γ in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145: 4306-4310.
51. Liew, F. Y., Y. Li, and S. Millott. 1990. Tumour necrosis factor (TNF-α) in leishmaniasis. II. TNF-α-induced macrophage leishmanicidal activity is mediated by nitric oxide from L-arginine. Immunology 71: 556-559.
52. Wei, X. Q., I. G. Charles, A. Smith, J. Ure, G. J. Feng, F. P. Huang, D. Xu, W. Muller, S. Moncada, and F. Y. Liew. 1995. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375: 408-411.
53. Shiloh, M. U., J. D. MacMicking, S. Nicholson, J. E. Brause, S. Potter, M. Marino, F. Fang, M. Dinauer, and C. Nathan. 1999. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10: 29-38.
54. Fang, F. C. 1997. Perspectives series: host/pathogen interactions: mechanisms of nitric oxide-related antimicrobial activity. J. Clin. Invest. 99: 2818-2825.
55. Jensen, A. T., S. Gasim, A. Ismail, A. Gaafar, J. A. Kurtzhals, M. Kemp, A. M. El Hassan, A. Kharazmi, and T. G. Theander. 1998. Humoral and cellular immune responses to synthetic peptides of the Leishmania donovani kinetoplastid membrane protein-11. Scand. J. Immunol. 48: 103-109.
56. Sukumaran, B., P. Tewary, S. Saxena, and R. Madhubala. 2003. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine 21: 1292-1299.
57. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69: 4719-4725.
58. Ghosh, A., S. Labrecque, and G. Matlashewski. 2001. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19: 3169-3178.
59. Planelles, L., M. C. Thomas, C. Alonso, and M. C. López. 2001. DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect. Immun. 69: 6558-6563.
60. Saha, B., H. Nanda-Roy, A. Pakrashi, R. N. Chakrabarti, and S. Roy. 1991. Immunobiological studies on experimental visceral leishmaniasis. I. Changes in lymphoid organs and their possible role in pathogenesis. Eur. J. Immunol. 21: 577-581.
61. Diefenbach, A., H. Schindler, M. Röllinghoff, W. M. Yokoyama, and C. Bogdan. 1999. Requirement for type 2 NO synthase for IL-12 signaling in innate immunity. Science 284: 951-955.
62. Roach, T. I., A. F. Kiderlen, and J. M. Blackwell. 1991. Role of inorganic nitrogen oxides and tumor necrosis factor α in killing Leishmania donovani amastigotes in γ interferon-lipopolysaccharide- activated macrophages from Lshs and Lshr congenic mouse strains. Infect. Immun. 59: 3935-3944.
63. Murray, H. W. 1990. Effect of continuous administration of interferon-α in experimental visceral leishmaniasis. J. Infect. Dis. 161: 992-994.
64. Murray, H. W., B. Y. Rubin, and C. D. Rothermel. 1983. Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes: evidence that interferon-γ is the activating lymphokine. J. Clin. Invest. 72: 1506-1510.
65. Barral-Netto, M., R. Badaro, A. Barral, R. P. Almeida, S. B. Santos, F. Badaro, D. Pedral-Sampaio, E. M. Carvalho, E. Falcoff, and R. Falcoff. 1991. Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J. Infect. Dis. 163: 853-857.
66. Ho, J. L., R. Badaro, A. Schwartz, C. A. Dinarello, J. A. Gelfand, J. Sobel, A. Barral, M. B. Netto, E. M. Carvalho, S. G. Reed, et al. 1992. Diminished in vitro production of interleukin-1 and tumor necrosis factor-α during acute visceral leishmaniasis and recovery after therapy. J. Infect. Dis. 165: 1094-1102.
67. Pisa, P., M. Gennene, O. Soder, T. Ottenhoff, M. Hansson, and R. Kiessling. 1990. Serum tumor necrosis factor levels and disease dissemination in leprosy and leishmaniasis. J. Infect. Dis. 161: 988-991.
68. Ghalib, H. W., M. R. Piuvezam, Y. A. Skeiky, M. Siddig, F. A. Hashim, A. M. el-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Invest. 92: 324-329.
69. Karp, C. L., S. H. el-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-γ. J. Clin. Invest. 91: 1644-1648.
70. Murray, H. W., C. Montelibano, R. Peterson, and J. P. Sypek. 2000. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J. Infect. Dis. 182: 1497-1502.
71. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30: 2935-2943.
72. Kenney, R. T., D. L. Sacks, A. A. Gam, H. W. Murray, and S. Sundar. 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177: 815-818.
73. Kamogawa, Y., L. A. Minasi, S. R. Carding, K. Bottomly, and R. A. Flavell. 1993. The relationship of IL-4- and IFN γ-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 75: 985-995.
74. Schuler, T., Z. Qin, S. Ibe, N. Noben-Trauth, and T. Blankenstein. 1999. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J. Exp. Med. 189: 803-810.
75. Platzer, C., G. Richter, K. Uberla, W. Muller, H. Blocker, T. Diamantstein, and T. Blankenstein. 1992. Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction. Eur. J. Immunol. 22: 1179-1184.
76. D'Andrea, A., X. Ma, M. Aste-Amezaga, C. Paganin, and G. Trinchieri. 1995. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: priming for IL-12 and tumor necrosis factor α production. J. Exp. Med. 181: 537-546.
77. Satoskar, A., H. Bluethmann, and J. Alexander. 1995. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect. Immun. 63: 4894-4899.
78. Kolb, J. P., N. Paul-Eugene, C. Damais, K. Yamaoka, J. C. Drapier, and B. Dugas. 1994. Interleukin-4 stimulates cGMP production by IFN-γ-activated human monocytes: involvement of the nitric oxide synthase pathway. J. Biol. Chem. 269: 9811-9816.
79. Bogdan, C., S. Stenger, M. Rollinghoff, and W. Solbach. 1991. Cytokine interactions in experimental cutaneous leishmaniasis: interleukin 4 synergizes with interferon-γ to activate murine macrophages for killing of Leishmania major amastigotes. Eur. J. Immunol. 21: 327-333.
80. McGuire, K. L., W. R. Duncan, and P. W. Tucker. 1985. Syrian hamster DNA shows limited polymorphism at class I-like loci. Immunogenetics 22: 257-268.